Reversibility of Rocuronium-induced Profound Neuromuscular Blockade with Sugammadex in pediatric patient.

Reversibility of Rocuronium-induced Profound Neuromuscular Blockade with Sugammadex in pediatric patient. - Reversibility of Rocuronium-induced Profound Neuromuscular Blockade with Sugammadex in pediatric patient.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013207

Enrollment

Registered

2014-02-20

Start date

2010-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical pediatric patients requiring general anesthesia.

Interventions

At reappearance of 1-2 PTC, a single bolus dose of 1.0mg/kg sugammadex was randomly administered. If there were residual neuromuscular blockade and recurarization, supplementary sugammadex were admini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients aged 1-23 month 2) Patients of ASA risk classification 1-3 3) Patients that a written informed consent was obtained to participate in this study.

Exclusion criteria

Exclusion criteria: 1)Patients had or suspected neuromuscular disorders. 2)Patients had a hstory of allergy to any medication used during anesthesia. 3) Patients had a history of malignant hyperthermia. 4)Patients had significant hepatic and renal disfunction.

Design outcomes

Primary

Measure	Time frame
The duration of the recovery to a TOF ratio of 0.9 and 90% of control in T1 after sugammadex was administered.	—

Countries

Japan

Contacts

Public ContactChihiro Sekijima

Saitama Children's Medical Center Department of Anesthesiology

c52yamaguchi@yahoo.co.jp048-758-1811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026